Canadian Firms Partner On Cannabinoid-Based Therapies For Mood Disorders
This article was originally published in The Pink Sheet Daily
Executive Summary
Anxiety and depression are on the list of disorders targeted by Cannasat/IntelGenx collaboration to develop cannabinoid-based CAT 320.